Abstract
This study investigated the efficacy and safety of intravenous treprostinil during the perioperative period in infants with non-restrictive ventricular septal defect (VSD) and severe pulmonary arterial hypertension (PAH) undergoing surgical VSD repair. This was a retrospective study. There were 79 infants with non-restrictive VSD and severe PAH receiving surgical treatment from January to December 2019 in our cardiac center. The patients were divided into the treprostinil group and control group according to whether intravenous treprostinil was used during the perioperative period. There were no significant differences in the preoperative characteristics, including age, sex, weight, ventricular size, or preoperative pulmonary artery pressure, between the two groups. Although the pulmonary artery pressure in both groups was significantly lower postoperatively than preoperatively, the postoperative pulmonary artery systolic pressure was significantly lower in group T than in group C. The postoperative mechanical ventilation time, ICU stay, and hospital stay in group T were shorter than those in group C. Treprostinil can be used effectively and safely to reduce the perioperative pulmonary artery pressure in infants with non-restrictive VSD and severe PAH undergoing surgical VSD repair.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cho YS, Park SE, Hong SK, Jeong NY, Choi EY (2017) The natural history of fetal diagnosed isolated ventricular septal defect. Prenat Diagn 37:889–893
Jin Y, Wang A, Wang Y, Wang Y, Wang W et al (2012) Natural history of prenatal ventricular septal defects and their association with foetal echocardiographic features. Cardiol Young 22:323–326
Correia Martins L, Lourenço R, Cordeiro S, Carvalho N, Mendes I et al (2016) Catch-up growth in term and preterm infants after surgical closure of ventricular septal defect in the first year of life. Eur J Pediatr 175:573–579
Narin N, Pamukcu O, Tuncay A, Baykan A, Sunkak S et al (2018) Percutaneous ventricular septal defect closure in patients under 1 year of age. Pediatr Cardiol 39:1009–1015
Scully BB, Morales DL, Zafar F, McKenzie ED, Fraser CD Jr et al (2010) Current expectations for surgical repair of isolated ventricular septal defects. Ann Thorac Surg 89:544–549
Aydemir NA, Harmandar B, Karaci AR, Sasmazel A, Bolukcu A et al (2013) Results for surgical closure of isolated ventricular septal defects in patients under one year of age. J Card Surg 28:174–179
Omelchenko A, Gorbatykh Y, Voitov A, Zaitsev G, Bogachev-Prokophiev A et al (2016) Perventricular device closure of ventricular septal defects: results in patients less than 1 year of age. Interact Cardiovasc Thorac Surg 22:53–56
Gabriels C, Buys R, Van de Bruaene A, De Meester P, Goetschalckx K et al (2019) Serial pulmonary vascular resistance assessment in patients late after ventricular septal defect repair. Int J Cardiol 282:38–43
Xi SB, Wang SS, Qian MY, Xie YM, Li JJ et al (2019) Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease. Chin Med J (Engl) 132:811–818
Pan X, Zheng Z, Hu S, Li S, Wei Y et al (2011) Mechanisms of pulmonary hypertension related to ventricular septal defect in congenital heart disease. Ann Thorac Surg 92:2215–2220
Levy M, Del Cerro MJ, Nadaud S, Vadlamudi K, Colgazier E et al (2018) Safety, efficacy and Management of subcutaneous treprostini infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol 264:153–157
Torres F, Rubin LJ (2013) Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther 11:13–25
Carpentier E, Mur S, Aubry E, Pognon L, Rakza T et al (2017) Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension. J Pediatr Surg 52:1480–1483
Park BY, Chung SH (2017) Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant: 2 Case reports. Medicine (Baltimore) 96:e7303
Olson E, Lusk LA, Fineman JR, Robertson L, Keller RL (2015) Short-term treprostinil use in infants with congenital diaphragmatic hernia following repair. J Pediatr 167:762–764
McIntyre CM, Hanna BD, Rintoul N, Ramsey EZ (2013) Safety of epoprostenol and treprostini in children less than 12 months of age. Pulm Circ 3:862–869
Alves JL Jr, Oleas FG, Souza R (2017) Pulmonary hypertension: definition, classification, and diagnosis. Semin Respir Crit Care Med 38:561–570
van der Feen DE, Bartelds B, de Boer RA, Berger RMF (2017) Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J 38:2034–2041
Roth TS, Aboulhosn JA (2016) Pulmonary hypertension and congenital heart disease. Cardiol Clin 34:391–400
Santhanam H, Yang L, Chen Z, Tai BC, Rajgor DD et al (2018) A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol 254:75–83
Chen Q, Hong ZN, Zhang GC, Chen LW, Zhang QL et al (2018) Intraoperative device closure of isolated ventricular septal defects: experience on 1,090 cases. Ann Thorac Surg 105:1797–1802
McNicholas K, de Leval M, Stark J, Taylor JF, Macartney FJ (1979) Surgical treatment of ventricular septal defect in infancy Primary repair versus banding of pulmonary artery and later repair. Br Heart J 41:133–138
Maneenil G, Thatrimontrichai A, Janjindamai W, Dissaneevate S (2018) Effect of bosentan therapy in persistent pulmonary hypertension of the newborn. Pediatr Neonatol 59:58–64
El Midany AA, Mostafa EA, Azab S, Hassan GA (2013) Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure. Interact Cardiovasc Thorac Surg 17:963–968
Lawrence KM, Hedrick HL, Monk HM, Herkert L, Waqar LN et al (2018) Treprostinil improves persistent pulmonary hypertension associated with congenital diaphragmatic hernia. J Pediatr 200:44–49
Acknowledgements
We highly acknowledge the contribution by the participating doctors: Dao-zhong Chen, Feng Lin, Qi-min Wang, Zhong-yao Huang, Han-fan Qiu, Xiao-fu Dai, Xue-Shan Huang, Hui Zhang, Zeng-chun Wang from Union Hospital, Fujian Medical University.
Funding
This study was supported by the National Key Research and Development Program of China (2016YFC1301900).
Author information
Authors and Affiliations
Contributions
S-tH, NX and QC designed the study, performed the statistical analysis, participated in the operation, and drafted the manuscript. K-pS collected the clinical data, L-wC and HC provide financial and technical support. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Huang, ST., Xu, N., Sun, KP. et al. The Effect of Perioperative Administration of Treprostinil in Infants with Non-restrictive Ventricular Septal Defect and Severe Pulmonary Arterial Hypertension. Pediatr Cardiol 41, 1334–1339 (2020). https://doi.org/10.1007/s00246-020-02387-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-020-02387-y